13D Filings
Home
FAQ
ESSA Pharma Inc.
Amendment
Ownership

0.00%

Total Shares

0

Issuer CIK

1633932

CUSIP

29668H708

Event Date

Oct 8, 2025

Accepted

Oct 14, 2025, 05:30 PM

SEC EDGARView Original Filing
Reporting Persons (10)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
BIOTECHNOLOGY VALUE FUND L P
Partnership
0.00%000
BVF I GP LLC
Other
0.00%000
BIOTECHNOLOGY VALUE FUND II LP
Partnership
0.00%000
BVF II GP LLC
Other
0.00%000
Biotechnology Value Trading Fund OS LP
Partnership
0.00%000
BVF Partners OS Ltd.
CO
0.00%000
BVF GP HOLDINGS LLC
Other
0.00%000
BVF PARTNERS L P/IL
Investment Adviser
0.00%000
BVF INC/IL
CO
0.00%000
LAMPERT MARK N
Individual
0.00%000
Disclosure Items (4)

Security Title

Common Shares

Issuer Name

ESSA Pharma Inc.

Item 3 is hereby amended and restated to read as follows: As described in Items 4 and 5 below, the Reporting Persons no longer beneficially own any Shares.

Item 4 is hereby amended to add the following: Effective October 9, 2025, the Issuer was acquired by Xeno Acquisition Corp. (the "Purchaser") pursuant to an arrangement under Section 288 of the Business Corporations Act (British Columbia) involving the Issuer, XenoTherapeutics, Inc. (the "Parent"), Purchaser, a wholly-owned subsidiary of Parent, and XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025 and the plan of arrangement, pursuant to which, among other things, the Purchaser acquired all of the outstanding Shares in exchange for: (i) $0.124231 in cash per Share (excluding the approximately $1.69 of cash per Share previously distributed to the Issuer's shareholders) and (ii) one contingent value right per Share for potential cash payments of up to approximately $0.14 per Share. Accordingly, the Reporting Persons ceased to beneficially own any securities of the Issuer.

Percentage of Class

Item 5(a) is hereby amended and restated to read as follows: As described in Item 4 above, the Reporting Persons no longer beneficially own any Shares

Transactions

Item 5(c) is hereby amended and restated to read as follows: Except as set forth in Item 4 above, the Reporting Persons have not entered into any transactions in the securities of the Issuer during the past 60 days.

Date of 5% Ownership

Item 5(e) is hereby amended and restated to read as follows: As of October 9, 2025, the Reporting Persons ceased to be the beneficial owners of more than 5% of the outstanding Shares.